Apogee Therapeutics (APGE) Liabilities and Shareholders Equity (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 81.14% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 billion (up 15.42% YoY) and the FY2025 annual result came in at $937.1 million, up 24.3% from the prior year.
• Liabilities and Shareholders Equity rose to $1.3 billion in Q1 2026 per APGE's latest filing, from $937.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.3 billion in Q1 2026 and bottomed at $130.7 million in Q2 2023.
• The 5-year median for Liabilities and Shareholders Equity is $714.2 million (2025), against an average of $653.4 million.
• The widest annual swing landed in 2024, when Liabilities and Shareholders Equity jumped 512.75%; it then fell 19.34% in 2025.
• Tracing APGE's Liabilities and Shareholders Equity over 5 years: stood at $152.1 million in 2022, then soared by 163.99% to $401.4 million in 2023, then soared by 87.83% to $754.0 million in 2024, then increased by 24.3% to $937.1 million in 2025, then surged by 38.04% to $1.3 billion in 2026.
• Per Business Quant, the three latest APGE Liabilities and Shareholders Equity figures stand at $1.3 billion (Q1 2026), $937.1 million (Q4 2025), and $626.2 million (Q3 2025).

Peer Comparison